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Strengths and limitations of this study
 ► To the best of our knowledge, this is the first study 
that explores the clarity of Screening Tool of Older 
Persons’ potentially inappropriate Prescriptions/
Screening Tool to Alert to Right Treatment (STOPP/
START) criteria.
 ► Clarity ratings were scored independently by ap-
praisers who were experienced in applying STOPP/
START criteria in clinical practice.
 ► The scoring process remains partly subjective, 
however, consensus ratings show high inter- rater 
agreement.
 ► By evaluating the what, when and why of 
recommendations, element- specific strategies were 
formulated to improve their clarity.
AbStrACt
Objectives Appropriate prescribing in older people 
continues to be challenging. Studies still report a 
high prevalence of inappropriate prescribing in older 
people. To reduce the problem of underprescribing 
and overprescribing in this population, explicit drug 
optimisation tools like Screening Tool of Older Persons’ 
potentially inappropriate Prescriptions/Screening Tool 
to Alert to Right Treatment (STOPP/START) have been 
developed. The aim of this study was to evaluate the 
clinical applicability of STOPP/START criteria in daily 
patient care by assessing the clarity of singular criteria.
Design Quality appraisal study.
Methods For each of the 114 STOPP/START criteria V.2, 
elements describing the action (what/how to do), condition 
(when to do) and explanation (why to do) were identified. 
Next, the clarity of these three elements was quantified on 
a 7- point Likert scale using tools provided by the Appraisal 
of Guidelines for Research and Evaluation (AGREE) 
Consortium.
Primary and secondary outcomes The primary outcome 
measure was the clarity rating per element, categorised 
into high (>67.7%), moderate (33.3%–67.7%) or low 
(<33.3%). Secondary, factors that positively or negatively 
affected clarity most were identified. Additionally, the 
nature of the conditions was further classified into 
five descriptive components: disease, sign, symptom, 
laboratory finding and medication.
results STOPP recommendations had an average clarity 
rating of 64%, 60% and 69% for actions, conditions and 
explanations, respectively. The average clarity rating in 
START recommendations was 60% and 57% for actions 
and conditions, respectively. There were no statements 
present to substantiate the prescription of potential 
omissions for the 34 START criteria.
Conclusions Our results show that the clarity of the 
STOPP/START criteria can be improved. For future 
development of explicit drug optimisation tools, such 
as STOPP/START, our findings identified facilitators 
(high clarity) and barriers (low clarity) that can be used 
to improve the clarity of clinical practice guidelines 
on a language level and therefore enhance clinical 
applicability.
IntrODuCtIOn
Clinical practice guidelines (CPGs) are 
instruments intended to provide guidance to 
healthcare professionals in patient care. Trans-
lation of healthcare knowledge, evidence and 
experience into clear recommendations for 
patient care, however, is challenging. Studies 
in the USA and the Netherlands suggest that 
about 30%–40% of patients do not receive 
care according to evidence based guidelines. 
A clear description of the desired behaviour 
has been associated with better compliance 
with guideline recommendations.1 2
Recommendations about safe and effec-
tive pharmacotherapy are an important 
part of CPGs. However, it is often unclear 
whether recommendations also apply to 
older people.3–5 A complicating factor is that 
older people experience more concomitant 
morbidities, while CPGs often focus on best 
treatment for a single disease. Ambiguity 
among prescribers about pharmacotherapy 
in older people results in inappropriate 
prescribing, which causes adverse drug 
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reactions, drug- related hospitalisations, decreased quality 
of life and even death.6 7
Due to the lack of clear statements in CPGs about (in)
appropriate prescribing in older people with multimor-
bidity, several explicit screening tools have been devel-
oped.8 9 The most widely used are the Beers criteria10 and 
the Screening Tool of Older Persons’ potentially inap-
propriate Prescriptions/Screening Tool to Alert to Right 
Treatment (STOPP/START) criteria.11 CPG recommen-
dations are rarely specified in precise behavioural terms 
such as what, how, when and why to stop or start a drug, 
while explicit screening tools are designed to make clear 
statements and therefore ease clinical implementation.2 
However, studies continue to report a high prevalence 
of inappropriate prescribing in older people.12–14 This 
suggests that implementation can still be improved.
Although STOPP/START criteria have shown good 
inter- rater reliability in studies involving physicians and 
(hospital)pharmacists working in geriatric units, data 
on how physicians less familiar with medication opti-
misation would interpret STOPP/START criteria are 
lacking.15 16 The question then arises whether the recom-
mended actions are formulated clearly enough to guide 
prescribers less experienced in geriatric patient care.
The aim of this study was to evaluate the clinical appli-
cability of STOPP/START criteria in daily patient care by 
assessing the clarity of singular criteria with the purpose 
of improving future clinical guideline recommendations 
for appropriate prescribing in older people.
MethODS
StOPP/StArt criteria
The STOPP/START criteria were first published in 2008 
and have been updated in 2015 to STOPP/START V.2.17 
STOPP/START is a product of two Delphi rounds by 19 
experts from 13 European countries.
For this study, the supplementary data of the corri-
gendum of the STOPP/START criteria V.2 as published 
in November 2017 were used.18 STOPP/START V.2 
consists of a list of 80 potentially inappropriate medica-
tions (STOPP criteria) and 34 potential prescribing omis-
sions (START criteria).
Clarity assessment
The Appraisal of Guidelines for Research & Evaluation 
(AGREE) II Instrument and Guideline Implementability 
Decision Excellence Model (GUIDE- M) were used to 
develop a framework to assess the clarity of language used 
in STOPP/START. AGREE II Instrument is an interna-
tionally validated tool to rate the quality of CPGs, devel-
oped by the AGREE Consortium.19 In addition to the 
AGREE II Instrument, AGREE developed a GUIDE- M.20 
This model identifies ‘communicating content’ as a core 
tactic for CPG implementability. Obviously, language is 
an important domain of this tactic. The language subdo-
main promotes a clear, simple and persuasive message.
The relevant part of the AGREE II Instrument (‘clarity 
of presentation’, domain 4, item 15) states that recom-
mendations should be ‘specific and unambiguous’, 
which is defined as ‘a concrete and precise description of 
which option is appropriate for which situation and for 
what population group’. In line with this statement and 
the corresponding section of the AGREE II Instrument, 
three elements were identified that influence the clarity 
of recommendations:
 ► Action: description of the recommended action, i.e. 
what to do and how to act?
 ► Condition: identification of the relevant target popu-
lation and statements about patients or conditions 
for whom the recommendations would apply or not 
apply, i.e. when?
 ► Explanation: identification of the intent or purpose of 
the recommended action, i.e. why?
In order to quantify the clarity of STOPP/START 
criteria, the three elements of each recommendation were 
rated independently on a 7- point Likert scale by a panel of 
two appraisers, consisting of a geriatric resident (CJAH) 
and a hospital pharmacy resident (BTGMS), both experi-
enced with the application of STOPP/START criteria in 
daily practice. The clarity for each of these three elements 
was rated from the perspective of a ‘junior’ physician or 
pharmacist with a basic level of knowledge (≤5 years of 
clinical postgraduate experience). The appraisers were 
trained with a rating guidance, developed and approved 
by senior clinicians (TE/EvP/IW/WK) prior to rating the 
elements independently. If ratings differed more than 1 
point, a senior hospital pharmacist/clinical pharmacolo-
gist (IW) or a senior geriatrician/clinical pharmacologist 
(WK) was consulted as a third appraiser until consensus 
was reached.
Descriptive components of conditions
In addition to the calculation of clarity ratings for the 
action, condition and explanation, the nature of the 
conditions was further explored. The condition identi-
fies the target population and is the most heterogeneous 
element. By stratifying the conditions into descriptive 
components, the nature of the components in relation 
to their clarity could be assessed. These components 
could lead to different strategies to optimise ‘specific and 
unambiguous’ wording in describing conditions.
The conditions were subdivided into five components 
that were considered essential for identification of the 
target population: disease, sign, symptom, laboratory 
finding and medication. Definitions of four components 
were based on the ontology as described by Scheuermann 
et al.21 Signs are defined as bodily features observed in 
a physical examination including measurements (e.g. 
blood pressure), while symptoms are bodily features expe-
rienced by a patient (e.g. restless legs). Since optimisation 
of polypharmacy is the main focus of the STOPP/START, 
the target population can also be described by (co)medi-
cation. Medication is not defined by Scheuermann et al. 
Therefore, medication was added as a fifth component 
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Figure 1 Distribution of clarity ratings for STOPP and 
START recommendations per element. Average clarity ratings 
for STOPP recommendations were 64%, 60% and 69% for 
actions, conditions and explanations, respectively. Average 
clarity ratings for start recommendations were 60% and 
57% for actions and conditions, respectively. STOPP/START, 
Screening Tool of Older Persons’ potentially inappropriate 
Prescriptions/Screening Tool to Alert to Right Treatment.
using the definition for medicinal products by the Euro-
pean Medicines Agency as ‘a substance or combination of 
substances that is intended to treat, prevent or diagnose 
a disease or to restore, correct or modify physiological 
functions by exerting a pharmacological, immunological 
or metabolic action’.22
Data analysis
Clarity ratings for each of the three elements (action, 
condition, explanation) were calculated as a percentage 
of the obtained scores given by appraiser 1 and 2 divided 






















This calculation method is in accordance with the 
approach provided by AGREE II Instrument. The scores 
of appraisers 1 and 2 were both replaced by the consensus 
score if a third appraiser was consulted. After scoring 
the elements, clarity ratings were categorised into low 
(<33.3%), moderate (33.3%–67.7%) and high (>67.7%).
Patient and public involvement
Since this is an appraisal study of clinical guideline 
recommendations intended to be used by clinicians, this 
research was done without patient involvement. Patients 
were not invited to comment on the study design and 
were not consulted to develop patient relevant outcomes 
or interpret the results. Patients were not invited to 
contribute to the writing or editing of this document for 
readability or accuracy.
reSultS
The elements ‘action’ and ‘condition’ in STOPP and 
START recommendations were rated on their clarity, 
resulting in 80 and 34 scores per element, respectively. 
The element ‘explanation’ was present in all but three 
(A1, A2, B11) STOPP recommendations, resulting in 77 
scores. None of the START criteria contained an expla-
nation to substantiate the prescription of potential omis-
sions. Therefore, Likert scores for explanations were only 
assessed in STOPP recommendations.
The agreement among the two appraisers for Likert 
scores was high and ranged from 76.3% (STOPP—condi-
tion) to 91.3% (STOPP—action). Forty- four out of 305 
(14.4%) scores were replaced after consensus meetings 
with a third appraiser. Replacements did not alter average 
Likert scores per element with more than 0.2 points 
compared with the average scores prior to consensus.
Average clarity ratings for STOPP recommendations 
were 64%, 60% and 69% for actions, conditions and 
explanations, respectively. Average clarity ratings for 
START recommendations were 60% and 57% for actions 
and conditions, respectively (figure 1).
In 80 STOPP and 34 START recommendations, the 
clarity ratings of 35 actions were categorised as high 
(30.7%), 65 as moderate (57.0%) and 14 as low (12.3%). 
Thirty- eight (33.3%), 67 (58.8%) and 9 (7.9%) conditions 
had a high, moderate or low clarity rating, respectively. In 
77 STOPP criteria, the clarity ratings of 41 (53.2%) expla-
nations were categorised as high, 35 (45.5%) as moderate 
and 1 (1.3%) as low.
Thirteen STOPP criteria (C1, C2, C4, C7, D6, D12, D13, 
E5, E6, F1, G1, H1 and H9) had high clarity ratings for 
all three elements. Four START criteria (B3, G3, I1 and 
I2) had high clarity ratings for both action and condition. 
Detailed information of clarity ratings per element for all 
individual STOPP/START criteria can be found in online 
supplementary data S1.
Elements with high (>67.7%) and moderate or low 
(≤67.7%) clarity ratings were analysed in more detail to 
identify factors that either positively or negatively affected 
‘specific and unambiguous’ language most. These find-
ings for actions, conditions and explanations with illustra-
tive examples for STOPP and START recommendations 
are presented in table 1.
The results of stratifying the element ‘condition’ into 
the five descriptive components medication, disease, sign, 
symptom and laboratory finding are shown per STOPP/
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Table 1 Main barriers and facilitators that affected clarity of the elements action, condition and explanation of STOPP/START 
recommendations
Barriers Example* (clarity rating, %)
Action
Lack of explicit drug (class) STOPP D7/8. Anticholinergics/antimuscarinics… (17%)
 ► ‘For example’ represents a non- limitative list and is therefore 
inconclusive
STOPP B10. Centrally acting antihypertensives (e.g. methyldopa, clonidine, 
moxonidine, rilmenidine, guanfacine)… (33%)
 ► Use of adjectives that need further investigation to allow use STOPP D14. First- generation antihistamines (17%)
START H1. High potency opioids… (17%)
Lack of drug deprescribing schedules while considered 
necessary
STOPP K2. Neuroleptic drugs (17%)
Starting dose and target dose not mentioned START A6. ACE inhibitor with systolic heart failure… (67%)
Lack of directions how and what to monitor after starting a drug START E1. Disease- modifying antirheumatic drug(DMARD)… (25%)
Condition
General—patient population for whom recommendations would 
not apply was not (clearly/unambiguously) defined
 ► In patients with a strong indication for a potentially 
inappropriate drug, it may be harmful to stop it
 ► In patients with potential omissions, warnings for important 
contra indications are lacking/not clearly defined
STOPP B5. …as first- line antiarrhythmic therapy in supraventricular 
tachyarrhythmias (33%)
START A2. …where vitamin K antagonists or direct thrombin inhibitors or 
factor Xa inhibitors are contraindicated (33%)
Medication—see also action
 ► Ambiguous adjectives were used
 ► Description of drug therapy (substance/dosage) not specific 
enough
STOPP D2. …as first- line antidepressant treatment (33%)
START E7. …in patients taking methotrexate (33%)
Disease—clinical interpretation of ‘disease (state)’ for defining 
population needed
STOPP D1. …with dementia, narrow angle glaucoma, cardiac conduction 
abnormalities, prostatism or prior history of urinary retention (33%)
START A5. …with a documented history of coronary, cerebral or 
peripheral vascular disease (33%)
Sign—measurement or scores were not described 
unambiguously
STOPP H2. …with severe hypertension or severe heart failure (33%)
START E1. …with active, disabling rheumatoid disease (42%)
Symptom—symptoms were not described unambiguously STOPP K- section. Not clear whether the occurrence of ‘falls’—as mentioned 
only in the title of section K—is a prerequisite for the applicability of the 
recommendation or only used to address the increased risk of falls. If ‘falls’ is 
considered a condition, the frequency of ‘falls’ is not specified. (0%)
STOPP D10. …unless sleep disorder is due to… (33%)
START C2. …with persistent major depressive symptoms (33%)
Laboratory finding—parameters lack clear cut- off levels with 
reference ranges
START C6. …once iron deficiency and severe renal failure have been 
excluded (33%)
Explanation
Risk of continuing therapy not clearly described: explanation 
does not cover clinical relevance of benefit/harm balance 
(specific adverse drug reactions, toxicity).
STOPP D7. …(risk of anticholinergic toxicity) (17%)
START N/A
Facilitators Example* (clarity rating, %)
Action
Drugs were specified on individual drug level and—if 
necessary—route/dosage was specified
STOPP C7. Ticlopidine… (100%)
START A2. Aspirin (75–160 mg once daily)… (92%)
Condition
Medication—see also action
Specific description of drug therapy (substance/dosage) to 
clearly identify the target population (i.e. patients using a certain 
drug regimen).
 
STOPP B3. …in combination with verapamil or diltiazem (92%)
START I2. …at least once after age 65 according to national guidelines 
(83%)
Disease—diseases clearly described, the target population 
could be easily identified
STOPP H9. …in patients with a current or recent history of upper 
gastrointestinal disease that is, dysphagia, oesophagitis, gastritis, 
duodenitis or peptic ulcer disease, or upper gastrointestinal bleeding 
(92%)
START C4. …for primary open- angle glaucoma (100%)
Signs—signs clearly described as scores or measurements and 
therefore unambiguous
START B3. …with documented chronic hypoxaemia (i.e. pO2 <8.0 kPa or 
60 mm Hg or SaO2 <89%) (92%)
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Facilitators Example* (clarity rating, %)
Laboratory findings—clear cut- off levels with reference ranges 
present
STOPP E6. …if eGFR <30 mL/min/1.73 m2 (100%)
Explanation
Risk of discontinuing clearly described STOPP D5. …(no indication for longer treatment; risk of prolonged 
sedation, confusion, impaired balance, falls, road traffic accidents; all 
benzodiazepines should be withdrawn gradually if taken for >2 weeks 
as there is a risk of causing a benzodiazepine withdrawal syndrome if 
stopped abruptly) (100%)
START N/A
*The examples shown are selected from elements with low and moderate (≤67.7%) clarity ratings for barriers and from high (>67.7%) clarity ratings 
for facilitators to substantiate the main findings. An overview of all clarity ratings can be found in the online supplementary data S1.
eGFR, estimated glomerular filtration rate; N/A, not applicable; pO2, partial pressure of oxygen; SaO2, arterial oxygen saturation; STOPP/START, 
Screening Tool of Older Persons’ potentially inappropriate Prescriptions/Screening Tool to Alert to Right Treatment.
Table 1 Continued
Figure 2 Clarity ratings of conditions for STOPP and start 
criteria related to five descriptive components. Green, orange 
and red colours correspond with high (>67.7%), moderate 
(33.3%–67.7%) or low (<33.3%) clarity ratings of conditions. 
STOPP/START, Screening Tool of Older Persons’ potentially 
inappropriate Prescriptions/Screening Tool to Alert to Right 
Treatment.
START recommendation in figure 2. Clarity ratings were 
scored on the level of condition as an element and not on 
the sublevel of the five descriptive components. There-
fore, all components of one condition share the same 
colouring for their clarity.
In 33 (41%) STOPP criteria and 17 (50%) START 
criteria, the condition consisted of more than one 
component. No strong association was found between 
the clarity of conditions and the nature of the descriptive 
components, as the clarity ratings of the condition section 
varied regardless of the nature of the component. 
However, laboratory findings used to identify the target 
population were discovered to have the highest clarity 
rating compared with other descriptive components in 
STOPP recommendations; 9 out of 13 laboratory- based 
conditions had a high clarity rating (>67.7%).
DISCuSSIOn
Main findings
In this study, we evaluated the clinical applicability of 
STOPP/START criteria in daily patient care by assessing 
the clarity of singular criteria. We found that 13 out of 80 
STOPP and 4 out of 34 START criteria had a high clarity 
rating for the three elements action, condition and expla-
nation. To improve clarity of recommendations, element- 
specific strategies can be formulated (table 1).
Actions were considered unclear if recommendations 
included non- explicitly specified drug classes (e.g. ‘anti-
cholinergics’). To improve clear description of the action 
(what and how) we advise to specify drugs at an individual 
substance level. The addition of how to start or stop a 
drug (immediately vs gradually, including monitoring 
guidelines and deprescribing schedules), route of admin-
istration and dosage were considered necessary for some 
actions to further improve clarity.
The definition of the condition (the when) had the 
lowest average clarity rating in both START and STOPP. 
Low clarity ratings for conditions resulted from insuffi-
cient distinctiveness in the identification of patients for 
whom recommendations do or do not apply. Conditions 
were described by medication, diseases, signs, symp-
toms and laboratory findings. To increase the clarity of 
the conditions, laboratory findings and signs have the 
highest potential to be optimised by adding statements 
about clear cut- off levels (e.g. ‘potassium >5.0 mmol/L’ 
instead of ‘hyperkalaemia’) and measurements (e.g. 
‘systolic blood pressure >160 mm Hg’ instead of ‘uncon-
trolled severe hypertension’). For conditions defined by 
medication use, the same improvements as suggested for 
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actions apply. In some cases even a description on a drug 
substance level was not specific enough. For instance, folic 
acid for patients on methotrexate therapy (START E7) 
only applies to patients using a low dose, weekly metho-
trexate schedule and not for patients on high dose meth-
otrexate. In such cases, a more detailed description of a 
drug dosage, route or indication was deemed necessary. 
Conditions described by diseases—like ‘heart failure’—
might seem clear at first, but often need further specifi-
cation (reduced vs preserved ejection fraction) to avoid 
ambiguity. Moreover, international cardiology guidelines 
distinguish between these subtypes of heart failure, subse-
quently affecting treatment recommendations. Adher-
ence to terminology of internationally used dictionaries 
to describe diseases, such as International Classification 
of Primary Care (ICPC) and International Classification 
of Diseases (ICD), could be a solution.
Furthermore, no explanations were present for START 
criteria to substantiate why a potential omitted drug 
should be initiated. Even though the reason to start a 
drug might seem obvious in most cases, the risk–benefit 
balance should always be addressed to assist a physician’s 
decision- making process whether or not to expose a 
patient to additional drug therapies.
Other remarks
STOPP/START criteria provide best evidence- based prac-
tices for the overtreatment and undertreatment of single 
conditions. However, it should be noted that STOPP/
START criteria provide conflicting recommendations. 
For example, if a patient has a clear indication for a beta 
blocker to treat ischaemic heart disease (START A7), this 
is contradicted if a patient is already using verapamil or 
diltiazem (STOPP B3). Merging such recommendations 
could increase implementation and prevent potential 
patient harm by overlooking relevant contraindications.
Besides making the what, how, when and why as clear as 
possible, guideline developers should consider whether 
recommendations are tailored for its intended end users 
(i.e. the who). Explicit screening tools to detect inappro-
priate prescribing in older people, such as Beers criteria 
and STOPP/START, are likely to be developed to reach 
all professionals involved in prescribing, as all prescribers 
encounter the problem of underprescribing and over-
prescribing in older people. Clinicians with high affinity 
for geriatric medicine may not need explicit treatment 
recommendation to provide best patient care, whereas 
some clinicians—such as surgical specialists—who treat 
older people but may be less experienced with (in)appro-
priate prescribing in older people, probably require more 
clear guidance. Clear recommendations are therefore 
important to reach all prescribers, because the success 
of STOPP/START criteria as an intervention depends on 
its integration and implementation in clinical practice.23 
Some recommendations may be best applied by physi-
cians with a certain expertise, such as to start an ‘acetyl-
cholinesterase inhibitor for mild- to- moderate Alzheimer’s 
dementia or Lewy body dementia (START C3)’. In such 
cases, the focus for all clinicians should probably be the 
recognition and detection of a potential omission, rather 
than to actually start drug treatment. An explicit action 
could be to refer such patients to a geriatrician or neurol-
ogist, thus separating the trigger for potential undertreat-
ment from the actual prescriber.
Strengths and limitations
To the best of our knowledge, this is the first study that 
explores the clarity of STOPP/START criteria. By system-
atically reviewing the clarity of the given action, condition 
and explanation, we identified facilitators (high clarity) 
and barriers (low clarity) that may be used to improve the 
content on a language level. As a result, element- specific 
strategies can be extracted to improve items requiring 
refinement. Although no previous studies have reviewed 
the clarity of singular recommendations of explicit 
drug screening tools, comparable research has been 
conducted concerning clarity of monitoring instructions 
in CPGs and drug labels. Their conclusions to improve 
ambiguous instructions concerning the monitoring of 
laboratory values are in line with our suggestions to add 
clear statements about the what, why, when and how of 
recommendations.24 25
Moreover, studies to refine the methodology of devel-
oping deprescribing guidelines to facilitate the depre-
scribing process were conducted.26 27 A good example 
are the tools provided by the Bruyère Research Institute, 
based on their research about developing deprescribing 
guidelines. The Bruyère research group has published 
evidence- based CPGs (for instance how to deprescribe 
benzodiazepines), accompanied by clear algorithms 
including well- described populations (including for 
which patients the recommendation does not apply), a list 
of available drugs and dosages, monitoring recommenda-
tions and tapering regimes, thereby complementing the 
clarity some STOPP- recommendations are lacking.28
Tools that have been developed to review the quality of 
entire CPGs underline the importance of clear and unam-
biguous recommendations,29 but no validated tool exists 
to date to rate singular clinical recommendations. As 
clarity of presentation is both part of the AGREE II Instru-
ment and described by GUIDE- M, we used tools from the 
AGREE Consortium to develop a review method. More-
over, the AGREE II Instrument is internationally formally 
endorsed for guideline assessment and provides a Likert 
scale that allowed us to quantify clarity.
Clarity ratings were scored by appraisers who are 
experienced in applying STOPP/START criteria in clin-
ical practice, as they contributed to a large multicentre, 
randomised controlled trial that evaluated the impact of a 
STOPP/START- based medication review in older people 
with polypharmacy. We believe that these experiences 
allowed clear identification of difficulties prescribers not 
familiar with STOPP/START may encounter. Although 
the scoring process remains partly subjective, the 
consensus ratings show high inter- rater agreement. Differ-
ences (>1 point) were discussed with a third appraiser 
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and consensus was reached for all items. Therefore, the 
final clarity ratings were considered reliable.
One concern of further specifying recommendations 
might be that they ‘replace’ important clinical consid-
erations made by physicians. However, guideline recom-
mendations are never meant to fully substitute clinical 
judgement to treat individual patients. This is why the 
explanation of a recommendation—next to the action 
and condition sections—is important for facilitating 
translation to an individual patient level.
A lack of strong evidence to support the recommended 
actions could impede formulating clear explanations. 
For example, clear statements on numbers needed to 
treat or numbers needed to harm might be difficult to 
extract from currently available evidence. In such cases, 
the addition of the strength of recommendations and 
supporting evidence could further direct clinicians. This 
is also endorsed by internationally renowned CPG quality 
assessment tools from AGREE and Grading of Recom-
mendations Assessment, Development and Evaluation 
(GRADE).30
Furthermore, our study only highlights barriers that 
could be optimised to prevent unintentional deviations 
from STOPP/START due to unclear language. Apart from 
the clarity of presentation, many other factors attribute to 
clinical implementation of evidence- based recommenda-
tions.27 31
Implications
To clarify the action, condition and explanation sections 
of a recommendation, a more detailed statement is often 
required. This may directly affect choices regarding 
the presentation of recommendations. In addition to 
improvements in ‘language’, the ‘format’ of a guideline 
could have a high impact on applicability as well. In a 
time where almost all evidence- based knowledge is elec-
tronically requested, a dynamic, electronic format could 
be used to integrate information that will improve clarity 
of presentation without making recommendations too 
extensive. Integrating clinical rules within electronic 
healthcare systems—with an option to request more 
detailed information—could contribute to a continuing 
learning cycle as part of (but without slowing down) the 
usual care process. For example, a drug class (stop benzo-
diazepines) may be provided with a hyperlink including 
information on drug substance levels (ATC5- codes) 
and a deprescribing tool, accessible on request. Once a 
prescriber has become familiar with all the details of a 
certain recommendation, such information is no longer 
required. However, converting recommendations into 
effective software assistance starts with a clear message of 
the initial statements.
To make the current version of STOPP/START 
criteria suitable for software engines, multiple multi-
disciplinary expert rounds turned out to be necessary 
to reach consensus on how to interpret ambiguous 
wordings.32 For instance, due to different lists of anti-
cholinergic drugs in current literature, expert opinion 
is needed to translate this drug class to clinically rele-
vant, individual drugs with high anticholinergic burden. 
Furthermore, it was found that some recommendations, 
such as to ‘stop any drug beyond the recommended 
duration (STOPP A3)’ were too general or unspecific to 
convert into an algorithm. Selecting specific recommen-
dations concerning potentially inappropriate long- term 
use of medication, such as long- term corticosteroids 
(>3 months) as monotherapy for rheumatoid arthritis 
(STOPP H4) or continuing bisphosphonates >5 years 
without evaluating efficacy (not a criterion), will prob-
ably result in a better uptake among clinicians and 
can be easily integrated into clinical decision support 
systems. Consequently, the lack of clear statements may 
impede software implementation.32 33
Another advantage to present clear recommendations 
in an electronic, dynamic format is that content could be 
easily modified based on updates in evidence, country- 
specific guidelines, available drugs and local expertise. 
Collaboration of guideline developers with experts in 
medical informatics for considering content formatting 
could, therefore, be of great value to facilitate future 
implementation of recommendations in clinical practice.
Conclusion
In conclusion, for future development of CPGs, our 
findings provide direction to assure the clarity of recom-
mendations. We believe in the opportunity to transform 
STOPP/START from a tool to detect inappropriate 
prescribing to a guideline that provides clear statements 
on how to act after detection. The use of specific and 
unambiguous language in CPG recommendations is 
likely to assist physicians in prescribing the right drug to 
the right patient at the right time.
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